Enhancing Innate Anti-Viral Resistance Through A Community-Based Intervention - Generation Xchange

About

Brief Summary

This randomized controlled trial will test whether a recently developed community-based intergenerational mentoring program known as Generation Xchange (GenX) can enhance antiviral resistance in older African-American women and men in a low-SES urban community. Additional studies will identify the biological processes that promote resistance to respiratory virus infections and viral disease in older African-American women and men.

Primary Purpose
The main objective of the intervention(s) being evaluated by the clinical trial. Learn more
Basic science
Study Type
The nature of the investigation or investigational use for which clinical study information is being submitted. Learn more
Interventional
Phase
Phase 1

Eligibility

Gender
All
Healthy Volunteers
Yes
Minimum Age
50 Years
Maximum Age
N/A

Inclusion Criteria:

  • Participating in the GenX intergenerational mentoring program
  • All GenX mentors > 50 years of age are eligible to participate in this research
  • GenX program participation requires:
  • Reside in neighborhood of GenX schools (South-Central Los Angeles)
  • Pass basic literacy and cognitive function tests

Exclusion Criteria:

  • Any health condition that would put participant at risk by enrollment/participation

Join this Trial

Enrolling by Invitation
These studies are not open to everyone who meets the eligibility criteria, but only to people in that particular population, who are specifically invited to participate.
Study Stats
Protocol No.
21-001388
Category
Infectious Diseases
Principal Investigator
Teresa Seeman
Contact
  • Steven Cole
Location
  • UCLA Westwood
For Providers
NCT No.
NCT05534425
For detailed technical eligibility, visit ClinicalTrials.gov.